FDA: GSK's Zofran might increase risk of abnormal heart rhythm

09/15/2011 | Wall Street Journal, The

The FDA is investigating the safety of GlaxoSmithKline's Zofran, or ondansetron, because of concern that the treatment increases the risk of abnormal heart rhythm. Zofran prevents nausea and vomiting in patients undergoing chemotherapy, surgery and radiotherapy. The FDA said it will add recommendations to Zofran's label, including electrocardiogram monitoring in certain patients.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC